The life sciences industry continues to face many unique anti-corruption challenges associated with the reality of doing business in jurisdictions around the world with complex regulations and deep public sector involvement in the provision of health care services. Unlike many multinationals, life sciences companies must contend with government involvement in nearly every aspect of their business: from research and development to approval and production all the way through distribution and the final sale. Anti-corruption enforcement from U.S. agencies and others across the globe is trending upward (in both frequency and the size of financial penalties) and there are strong indications of a continued emphasis on the health care sector over the next several years. Examination of recent settlements in the industry provide insight into some of the unique risks facing life sciences companies, as well as recommended best practices.
Click below to read the full article.